The past year has continued to see an increase in US case law developments in the area of pharmaceutical antitrust. This article focuses on four areas of pharmaceutical antitrust litigation that have been most active:
- Recent dismissals of reverse payment allegations
- Increasing class certification scrutiny in pharmaceutical antitrust matters
- Challenges to pharmaceutical manufacturers' pricing practices
- The first pharmaceutical antitrust litigations concerning biosimilar competition
Click here to download the full PDF: "United States: Pharmaceutical Antitrust 2021"
Click here to view our EU report: "European Union: Pharmaceuticals"
This article was published by Global Competition Review in the Americas Antitrust Review 2021.
This publication is provided for your convenience and does not constitute legal advice. This publication is protected by copyright.